Allogene Therapeutics (ALLO) Projected to Post Quarterly Earnings on Tuesday

Allogene Therapeutics (NASDAQ:ALLO) is expected to announce its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $0.0020 million for the quarter. Investors can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 5:00 PM ET.

Allogene Therapeutics (NASDAQ:ALLO) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.08. On average, analysts expect Allogene Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Allogene Therapeutics Stock Performance

Shares of NASDAQ:ALLO traded down $0.07 during midday trading on Tuesday, reaching $2.20. The company’s stock had a trading volume of 1,613,257 shares, compared to its average volume of 8,483,239. The firm has a market capitalization of $537.38 million, a price-to-earnings ratio of -2.52 and a beta of 0.46. The firm has a 50 day moving average price of $2.41 and a two-hundred day moving average price of $1.79. Allogene Therapeutics has a fifty-two week low of $0.86 and a fifty-two week high of $4.46.

Analyst Ratings Changes

A number of research firms recently weighed in on ALLO. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Allogene Therapeutics in a research note on Friday. Piper Sandler upped their price target on Allogene Therapeutics from $7.00 to $8.00 and gave the stock an “overweight” rating in a research note on Friday, March 13th. Wall Street Zen raised Allogene Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, February 22nd. Robert W. Baird upped their price target on Allogene Therapeutics from $7.00 to $9.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 14th. Finally, Argus upped their price target on Allogene Therapeutics from $1.60 to $3.85 and gave the stock a “market perform” rating in a research note on Tuesday, April 14th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Allogene Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.44.

Insiders Place Their Bets

In related news, CEO David D. Chang sold 47,763 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $2.47, for a total transaction of $117,974.61. Following the transaction, the chief executive officer directly owned 5,150,599 shares of the company’s stock, valued at approximately $12,721,979.53. This represents a 0.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders sold 72,183 shares of company stock worth $177,771. 13.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Allogene Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of ALLO. AQR Capital Management LLC purchased a new stake in shares of Allogene Therapeutics in the first quarter worth approximately $85,000. Goldman Sachs Group Inc. raised its stake in shares of Allogene Therapeutics by 177.9% in the first quarter. Goldman Sachs Group Inc. now owns 5,853,974 shares of the company’s stock worth $8,547,000 after purchasing an additional 3,747,397 shares during the last quarter. Jane Street Group LLC raised its stake in shares of Allogene Therapeutics by 578.7% in the first quarter. Jane Street Group LLC now owns 1,116,681 shares of the company’s stock worth $1,630,000 after purchasing an additional 952,158 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Allogene Therapeutics by 13.0% in the second quarter. Geode Capital Management LLC now owns 3,794,827 shares of the company’s stock worth $4,289,000 after purchasing an additional 435,389 shares during the last quarter. Finally, Rhumbline Advisers raised its stake in shares of Allogene Therapeutics by 14.0% in the second quarter. Rhumbline Advisers now owns 209,336 shares of the company’s stock worth $237,000 after purchasing an additional 25,628 shares during the last quarter. 83.63% of the stock is owned by hedge funds and other institutional investors.

About Allogene Therapeutics

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.